Thermostable CRISPR Detection Moves Closer to One-Pot Workflow
MB-CasFire™ is designed to solve a problem that has slowed many CRISPR diagnostic formats: the enzyme must keep working in the warm, salty reaction conditions needed for isothermal amplification. In this preprint, investigators describe a CRISPR-Cas enzyme engineered from a naturally thermostable Cas12a to function as a plug-and-play component for DETECTR-style nucleic acid testing. The goal is straightforward, but technically demanding: amplify the target, recognize it, and report it in a single tube without moving material between steps.
That single-tube architecture matters because every transfer adds time, cost, and contamination risk. It also places a harsher burden on the detection enzyme than a standard post-amplification readout does. If the CRISPR nuclease loses activity in amplification buffer, the assay loses the signal clarity that makes rapid molecular testing useful at the bench and in the field.
Engineering a Cas12a That Can Keep Up With Amplification Chemistry
The work centers on a thermostable enzyme called MB-CasFire, built from a naturally heat-tolerant Cas12a scaffold and optimized for stronger performance under amplification conditions. The practical aim is not just thermal survival; it is compatibility with the chemistry of one-pot testing. Isothermal methods such as loop-mediated isothermal amplification LAMP and nicking enzyme amplification reaction NEAR can generate abundant nucleic acid product without thermocycling, but they also create a reaction environment that can be hostile to a conventional CRISPR readout enzyme.
MB-CasFire remained active at elevated temperatures in amplification buffers and supported one-pot detection with both LAMP and NEAR. In operational terms, this means the assay no longer depends on a separate post-amplification transfer before Cas-based detection can occur. The signal-to-noise ratio improved enough to support precise nucleic acid detection, which is the central requirement for any diagnostic system that aims to distinguish true target presence from background reactivity.
A single reaction chamber can simplify assay architecture without sacrificing analytical specificity.
OnePot DETECTR Uses Standard Reagents and Familiar Formats
The assay format described here, called OnePot DETECTR, was built to be compatible with commercially available isothermal master mixes, including products from New England Biolabs. That compatibility is important because diagnostic workflows often fail in translation when they depend on custom reagents or highly specialized handling. A system that can be assembled from standard materials is easier to reproduce, easier to distribute, and easier to adapt across laboratories with different infrastructure.
The preprint frames MB-CasFire as a “plug-and-play” enzyme because the reagent can be dropped into established DETECTR-style assay logic without requiring a complete redesign of the platform. The detection chemistry remains familiar: a target sequence is amplified, the CRISPR enzyme is activated by the target, and trans-cleavage of a reporter generates the readout. The novelty sits in the enzyme’s durability and its compatibility with the high-temperature, amplification-rich environment that one-pot assays demand.
Pathogen Detection in Nasal Swabs and Urine Samples
To show that the platform is more than a biochemical curiosity, the investigators used MB-CasFire in assays for clinically relevant targets. SARS-CoV-2 was detected in nasal swab samples with a LAMP-based OnePot DETECTR assay, and Neisseria gonorrhoeae was detected in urine samples with a NEAR-based OnePot DETECTR assay. These examples matter because they reflect very different sample types and diagnostic use cases, yet the same enzyme design was able to support both workflows.
The nasal swab application speaks to respiratory pathogen testing, where speed, simplicity, and contamination control are major operational concerns. The urine-based gonorrhea assay points to sexually transmitted infection testing, where molecular precision is essential and sample handling often needs to be streamlined for higher-throughput or point-of-care use. In both settings, a one-pot reaction can reduce the number of manual steps between specimen and result.
Multiplexing and SNP Discrimination Extend the Use Case
MB-CasFire also functioned in multiplex detection and in single-nucleotide polymorphism discrimination assays used for antibiotic resistance genotyping. This is an important extension because many molecular diagnostics do not simply ask whether a pathogen is present. They need to distinguish among closely related sequences, identify resistance-associated variants, or detect more than one target in the same reaction.
Single-nucleotide discrimination is a particularly demanding test of assay specificity. A CRISPR system that can resolve small sequence differences under one-pot conditions has a stronger claim to clinical utility than one that only detects high-copy targets in an idealized bench setup. The preprint suggests that MB-CasFire retained enough precision to support those more exacting applications, even while operating in the same reaction space as isothermal amplification.
Diagnostic Simplicity Still Depends on Analytical Control
The appeal of one-pot CRISPR diagnostics is obvious: fewer steps, less contamination risk, and a workflow that fits better with decentralized testing. Yet the chemistry is unforgiving. Amplification increases target abundance, but it also changes salts, temperatures, and reaction kinetics in ways that can destabilize a poorly matched nuclease. MB-CasFire was engineered to meet that challenge, and the data presented here suggest that the enzyme can keep detection and amplification synchronized rather than forcing them into separate stages.
That synchronization is not a cosmetic improvement. It is what allows a CRISPR diagnostic to move from a clever molecular demonstration toward something that could be assembled reproducibly from standard components. The workflow still needs peer review and broader validation, but the technical barrier it addresses is a real one: a detection enzyme must remain active where amplification lives, not just where ideal assay conditions happen to exist.
The preprint closes with a concrete claim rather than a speculative flourish: MB-CasFire simplifies assay architecture for CRISPR-based detection systems that amplify, recognize, and report nucleic acid targets in a single reaction without thermocycling. Any clinical deployment will depend on validation beyond this early report, including performance in broader sample sets, robustness across operators, and confirmation that the one-pot format holds up outside the development laboratory.